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Abstract
Familial renal glycosuria is an inherited disorder resulting in glucose excretion in the urine
despite normal blood glucose concentrations. It is most commonly due to mutations in the
SLC5A2 gene coding for the glucose transporter SGLT2 in the proximal tubule. Several
drugs have been introduced as means to lower glucose in patients with type 2 diabetes tar-
geting SGLT2 resulting in renal glycosuria, but no studies have addressed the potential
effects of decreased renal glucose reabsorption and chronic glycosuria on the prevention of
glucose intolerance. Here we present data on a large pedigree with renal glycosuria due to
two mutations (c.300-303+2del and p.A343V) in the SLC5A2 gene. The mutations, which in
vitro affected glucose transport in a cell line model, and the ensuing glycosuria were not
associated with better glycemic control during a follow-up period of more than 10 years.
One individual, who was compound heterozygous for mutations in the SLC5A2 gene suf-
fered from severe urogenital candida infections and postprandial hypoglycemia. In conclu-
sion, in this family with familial glycosuria we did not find any evidence that chronic loss of
glucose in the urine would protect from deterioration of the glucose tolerance over time.
Introduction
Familial renal glycosuria (FRG) is a rare disorder that is characterized by decreased renal reab-
sorption of glucose. In most published cases this abnormality is due to mutations in the
SLC5A2 gene, which encodes for the sodium glucose co-transporter 2, SGLT2 [1–6]. SGLT2 is
the major glucose co-transporter in the proximal tubule responsible for 90% of the renal glu-
cose reabsorption while 10% is absorbed by the more distally located sodium glucose co-trans-
porter 1 (SGLT1). It is noteworthy that SGLT2 also is the target for antidiabetic therapy. FRG
is usually inherited in a co-dominant fashion with incomplete penetrance [2]. Although
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glucose loss in the urine can range from 1 to 150 g/1.73m2 FRG is generally considered as a
benign condition, apart from anecdotal reports of polyuria, increased frequency of urinary
tract infections and activation of the renin-angiotensin aldosterone system [7–9]. No studies
have addressed the potential effects of decreased renal glucose reabsorption and chronic gly-
cosuria on the prevention of glucose intolerance.
Early studies in rats reported beneficial effects of inhibition of the renal glucose reabsorption
by phlorizin on the glucose tolerance and prompted the introduction of SGLT2 inhibitors as
means to lower glucose in patients with type 2 diabetes. This treatment strategy was further jus-
tified by findings of increased SGLT2 expression and increased glucose uptake in the proximal
tubule in biopsies from type 2 diabetes patients [10] although it is not known whether the
increased expression is a cause or consequence of hyperglycemia. Furthermore, it has been
shown that inhibition of glucose reabsorption by SGLT2 inhibitors increases endogenous glu-
cose production and plasma glucagon concentrations in diabetic subjects [11,12], and nondia-
betic mice [13]. Notably, SGLT2 is also expressed in the alpha cells alongside SGTL1 [14]. Both
of these glucose transporters are down regulated in islets from donors with type 2 diabetes and
in ob/obmice after the development of hyperglycemia together with an increased expression of
glucagon mRNA [14].
Several SGLT2 inhibitors have been introduced for the treatment of type 2 diabetes and are
also being tested in patients with type 1 diabetes. The therapeutic window of this class of drugs
has been considered good with beneficial effects on weight and blood pressure and few other
side effects than a slightly increased frequency of genital mycotic infections that seldom leads
to discontinuation of the drug [15,16]. Therefore, these new drugs could also be considered for
the prevention of diabetes. However, studies on the potential effects of SGLT2 inhibitors on
prevention of diabetes are lacking. One possibility to address this question without testing the
drug in a non-diabetic population would be to study non-diabetic carriers with FRG for their
propensity to develop diabetes or deterioration of glucose tolerance. We did this in a large pedi-
gree with FRG followed by repeated oral glucose tolerance tests for more than 30 years, after
first confirming that their FRG was due to mutations in the SLC5A2 gene. In this family we
found no evidence that chronic loss of glucose in the urine would protect from deterioration of
the glucose tolerance over time.
Materials and Methods
Subjects
A family with renal glycosuria from the Botnia region on the west coast of Finland has been
followed clinically for the last 30 years [17]. In addition to renal glycosuria, 8 individuals
developed impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or type 2 diabe-
tes (T2D) (Fig 1) and the family were therefore followed by repeated oral glucose tolerance
tests (OGTT, 75 g glucose) as part of the Botnia Study [18]. To evaluate whether glucose loss
in the urine in individuals with glycosuria would affect glucose tolerance we calculated the
changes in the area under the OGTT curve (ΔAUCOGTT) between the first and last visit
(mean follow up time 10.5 years, range 3–22 years). AUCOGTT was calculated with the trape-
zoidal method from the plasma glucose concentrations at 0, 30, 60 and 120 minutes during
the OGTT. One female family member (No 45 in the pedigree, Fig 1) presented with marked
glycosuria associated with symptoms of postprandial hypoglycemia and severe chronic uri-
nary tract infections (predominantly candida infections). Under controlled conditions with a
daily intake of 160 grams of carbohydrates, she excreted 55.2 g glucose/24 hours. She died
from a gastric cancer at the age of 49 years. A paraffin embedded gastric biopsy was used for
extraction of her DNA. Thin sections of the tissue were carefully scraped off the block using a
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scalpel and put into xylene for paraffin removal and the DNA was extracted using the
QIAmp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions.
The DNA extracted from the paraffin embedded tissue was unfortunately not of sufficient
quality for sequencing; therefore two potentially functional mutations (c.300-303+2del and p.
A343V) were imputed from sequencing data from her husband, children and grandchildren
and then genotyped in the index case, family member 45, using a Taqman assay and a PCR
with genotype specific primers (S2 Table).
To investigate the prevalence of glycosuria in the general population we extracted data on
urine glucose excretions during OGTT from 4999 individuals part of the Botnia Study [18].
This was related to diagnosis of IGT/T2D using the Χ2 test.
The study was approved by the ethics committee at Vaasa Central Hospital, and written
informed consent was obtained from all participants or guardians on the behalf of the minors/
children participants.
Whole exome sequencing and validation genotyping
DNA was extracted from blood samples and one μg of high quality DNA was used for sample
preparation for sequencing using the TruSeq DNA sample preparation kit v2 (Illumina, CA,
USA) before whole exome capture with the TruSeq Exome Enrichment Kit (Illumina, CA,
USA) according to the manufacturer’s instructions. A paired end 2x100 base pair sequencing
was then performed on a HiSeq 2000 (Illumina, CA, USA).
After base calling and de-multiplexing using CASAVA 1.8.2 (Illumina, CA, USA) the fastq-
files were quality assessed with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) and aligned against Hs37d5 using Burrows-Wheeler Aligner (BWA) v. 0.6.8 [19]. The
Genome Analysis Tool Kit [20] (GATK) v. 1.6.2 was used on the resulting BAM-files for local
realignment around known indels (IndelRealigner), for marking of duplicate reads (MarkDu-
plicates) and for base quality recalibration (CountCovariates and TableRecalibration). Variants
were called using GATKs Unified Genotyper and variant recalibration (VariantRecalibrator
Fig 1. The pedigree of the family with glycosuria. Black symbols indicate that the person has IFG, IGT or
T2D (squares = men, circles = females), white symbols indicate normal glucose tolerance. Diagonally
hatched symbol indicates T1D (not included in the analysis). Plus and minus indicates positive or negative
test for glycosuria. First number under symbols indicates ID number. Genotyping of the deletion (c300-303
+2del) showed that 10 of 22 genotyped family members are heterozygous for the mutation. The carriers of the
deletion (c300-303+2del) are denoted with 0/1 and carriers of the reference allele are denoted with 0/0 while
carriers of the missense mutation (p.A343V) are denoted with 0/2.
doi:10.1371/journal.pone.0146114.g001
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and ApplyRecalibrations) [21]. This procedure was done according to the GATK best practices
(https://www.broadinstitute.org/gatk/guide/best-practices).
As most mutations that cause FRG are located in the SLC5A2 gene [22], the initial filtering
was restricted to variants within the region of this gene. Resulting variants were analysed with
SnpEff v3.0 [23] and SIFT [24] to evaluate functionality and potential effect of the variants on
the resulting protein. Only variants predicted to be detrimental to the protein were tested for
association with renal glycosuria in the family using Fisher’s exact test. The ExPASy Translate
tool [25] was used to predict the effect of mutations on the translation of the mRNA.
The selected variants were validated in 23 family members by genotyping using custom
made TaqMan assays (Life Technologies, CA, USA) according to the supplier’s instructions.
Functional studies expressing SGLT2 mutation in HEK293-cells
We also tested whether the missense mutation in the SLC5A2 gene (see below) influenced glu-
cose transport and reabsorption in the tubule by expressing the wild type (WT) and mutant
form of the protein (SGLT2) in HEK 293 [26] cells lacking the natural SGLT2 [27]. The WT
cDNA sequence (S1 table) of SLC5A2 was synthesized and mutated (GenScript USA Inc., NJ,
USA) and the resulting cDNA was cloned into the neomycin resistance containing
pCMV6-Neo vector (OriGene Technologies, Inc., MD, USA). The constructs were separately
transfected into the HEK293 cell line in triplicates, and successfully transfected cells were
selected using 0.8 mg/ml of G418 (Merk Millipore, MA, USA), an antibiotic often used to
select for neomycin resistant cells, for 14 days. The cells were subsequently cultured in
D-MEM (Cat# 41966029, Life Technologies, CA, USA) supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin with a 50 μg/ml maintenance dose of G418. SLC5A2
mRNA expression was measured by SYBR-green qPCR using SLC5A2mRNA specific prim-
ers designed to span exon junctions (S2 Table).
To evaluate the effect of the missense mutation in SLC5A2 on glucose transport the trans-
fected HEK293 cells were assayed using the Glucose Uptake Cell based Assay Kit (Cayman
Chemical, MI, USA). Triplicates of the WT and mutant SGLT2 cell lines and the untransfected
HEK 293 cell line were seeded at 2x104 cells per well in a 96-well plate and incubated over
night. The relative mRNA expression was measured to compare the transfection and transcrip-
tion efficiency of the six cell lines. The next morning, the cells were incubated in glucose and
serum free medium containing 150 μg/ml of the fluorescent glucose analogue 2-deoxy-2
[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-Glucose (2-NBDG) for 30 minutes. The cells
were then washed and treated according to the manufacturer’s instructions before measuring
fluorescence of the cells using an Infinite 200 Pro plate reader (Tecan, Männedorf, Switzer-
land). Untransfected cells were treated with the glucose uptake inhibitor Apigenin to control
for unspecific uptake and the signal was used as background in the measurements. Relative glu-
cose uptake was calculated as fluorescence normalized against WT-transfected signal and the
difference between the WT-transfected cells and the mutant-transfected cells was tested with
Student’s t-test.
Screening for SGLT2 mutations in the Botnia Study
To study how common these mutations in the SLC5A2 gene are in the general population we
screened 2584 samples from the Botnia study [18] for the c.300-303+2del mutation by geno-
typing them using a custom TaqMan assay (Life Technologies, CA, USA). Secondly, we
screened whole exome sequencing data from the GOT2D consortium for possibly damaging
variants in a total of 2760 samples.
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SLC5A2 and SLC5A1 expression in human pancreatic islets
As the expression of both SLC5A2 and SLC5A1 has been suggested to be affected in islets from
diabetic patients [14] we studied the expression of these two genes in 132 human islet samples
from donors with a wide range of glycemia [28] using STAR[29]-aligned RNA-sequence data
by the voom [30] and limma [31] R-packages. Expression values were expressed as the logarith-
mic count per million (log2CPM). The expression of SLC5A2 and SLC5A1 was correlated with
insulin and glucagon expression levels and SLC5A2 expression with glucagon secretion at 1
mM glucose using Pearson correlation. All p-values were FDR corrected. The islets were pro-
vided by the Human Tissue Lab EXODIAB/LUDC through the Nordic Transplantation Pro-
gram (http://www.nordicislets.org).
Results
Mutations in the SLC5A2 gene were associated with renal glycosuria in
the family
By sequencing the SLC5A2 gene in 23 members of the FRG family three novel and one previ-
ously reported variant were found, i.e. 3 single nucleotide variants (SNVs) and one 6 base pair
deletion (Table 1). Two SNVs were intronic in no known regulatory region, and the third SNV
was only seen in one of 23 samples, and therefor they were not considered any further. The
deletion (c.300-303+2del) removed the four last base pairs in exon three as well as two base
pairs of the conjunctive splice site and was by the ExPASy Translate tool [25] predicted to
cause a premature stop codon, resulting in a shorter 117 residue peptide (S1 Fig).
This heterozygous deletion (c.300-303+2del) segregated with glycosuria in 10 of 14 family
members (Fig 1). All carriers of the deletion (c.300-303+2del) excreted glucose in urine
(defined as having at least one positive quantitative or qualitative urine glucose tests) compared
with 5 out of 14 non-carriers (p = 0.003, Fig 2A). While this segregation was compatible with
co-dominant inheritance, the index case (family member 45) with the most severe form of gly-
cosuria, excreting 55.2 g glucose/24 hours compared to other family members excreting
between 0.2–20.7 g/24 hours, had only one copy of the mutation and, in contrast to our expec-
tations, was not homozygous for the deletion (see below).
In order to impute the genotype of the index case we genotyped her husband, her two chil-
dren and three grandchildren. Her husband did not carry any mutation in the SLC5A2 gene
but 4 variants were found in the children and the grandchildren (Table 1). Three of the variants
were intronic whereas the fourth variant (p.A343V) was a missense mutation in exon 9 of the
Table 1. Variants found in the SLC5A2 gene by whole exome sequencing of the family.
Chromosome:position ID REF/ALT Intron/exon SNPEff prediction SIFT prediction
16: 31495577* rs9924771 A/G Intron
16: 31495671* rs11646054 G/C Intron
16: 31495873 rs9934336 G/A Intron
16: 31496240 c.300-303+2del GGAATGT/G Exon FRAME_SHIFT(HIGH), SPLICE_SITE_DONOR(HIGH) N/A†
16: 31496471 . A/C Intron
16: 31498364* rs5816530 T/TCAAAAA Intron
16: 31499713 p.A343V C/T Exon NON_SYNONYMOUS_CODING(MODERATE) Damaging
† Only SNVs are scored by SIFT. The variants found in the region of SLC5A2 in the whole exome sequencing and the predicted functional consequence
of the variants, where applicable. The possible predictions of SNPEff are High, Moderate, Low and Modiﬁcation, and by SIFT Tolerated or Damaging.
Variants marked with star (*) were found in the sequencing of the children and grandchildren of subject no 45.
doi:10.1371/journal.pone.0146114.t001
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SLC5A2 gene also found in its heterozygous form in the daughters and one grandchild. Both
daughters presented with glycosuria while the grandchild did not (Table 2).
As the SNV was not found in the father of the offspring, it is likely that the missense muta-
tion (p.A343V) is inherited from the index case suggesting that she would be compound het-
erozygous for the deletion (c.300-303+2del) and the missense mutation (p.A343V). To test this
we performed TaqMan genotyping of the 6 bp deletion and PCR using genotype specific prim-
ers for the missense mutation of DNA from the index case. These analyses confirmed our
hypothesis that she indeed was compound heterozygous for mutations in the SLC5A2 gene as
Fig 2. Carriers of the deletion are not protected against deterioration of glycemic status A) glycosuria in carriers and non-carriers of the mutation
deletion (c300-303+2del). All but one of the non-carriers displaying glycosuria had impaired fasting glucose, impaired glucose tolerance or type 2 diabetes,
B) HbA1c at examination did not differ between carriers and non-carriers (p = 0.09), C) Area under the glucose curve during the last OGTT (p = 0.64), D)
Change in area under the glucose tolerance from the first to the last OGTT (p = 0.67, mean follow up time 11 years), E) Change in BMI during the follow-up
period. The white dots in the graphs represent non-diabetic individuals and the black dots individuals with impaired fasting glucose/impaired glucose
tolerance/type 2 diabetes. The error bars show the SD.
doi:10.1371/journal.pone.0146114.g002
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she carried both the 6 bp deletion (c.300-303+2del) and the missense mutation (p.A343V,
S2 Fig).
Glucose transport in kidney cells (HEK293) is impaired in carriers of the
p.A343V mutation
To confirm that the missense p.A343V mutation affected the glucose transport we expressed
the mutation in a human kidney cell line, HEK293, lacking the endogenous SGLT2 protein.
The cells expressing the p.A343V transporter showed decreased capability to transport glucose
over the cell membrane in vitro relative to the cells expressing the WT transporter (n = 12,
p = 0.02, Fig 3).
Influence of the SLC5A2mutations on change in the glucose tolerance
over time
Of 13 glycosuric family members, 5 had normal whereas 8 had abnormal glucose tolerance. To
confirm that the glycosuria was due to a reduced threshold for glucose reabsorption in the kid-
ney in these family members and not only a corollary of elevated plasma glucose we compared
the prevalence of glycosuria between individuals with normal and abnormal glucose tolerance
(IGT or T2D) and between those with the SLC5A2mutations (6 of whom also had abnormal
glucose tolerance). Among 4999 individuals from the Botnia study, 95% of all glycosuric indi-
viduals had IGT or T2D and, vice versa, 64% of patients with IGT/T2D had glycosuria (Χ2
p<0.0001). Although glycosuria was also present in 9.5% of the individuals with normal glu-
cose tolerance, these individuals had significantly higher glucose area under the curve during
OGTT compared to those without glycosuria (n = 323, 1005 mmoll-1min compared to 812
mmoll-1min, p = 0.001). To explore how common the c.300-303+2del mutation was in Fin-
land we genotyped 2584 individuals from Botnia for the c.300-303+2del mutation and identi-
fied 10 additional individuals from 5 families with the deletion. Next we analysed whole exome
sequence data from the GOT2D consortium including individuals from the Botnia region. Of
the 2760 screened individuals two carried the c.300-303+2del mutation and they both came
from the Botnia region. Both were glycosuric but they had also diabetes. In addition, in the
GOT2D data set we found 36 other missense variants in the SLC5A2 gene, 7 of which were pre-
viously reported in dbSNP [32].
To test whether chronic glycosuria as seen with the use of SGLT2 inhibitors would prevent
diabetes or deterioration of the glucose tolerance we assessed changes in the glucose tolerance
over time in glycosuric carriers and non-carriers of the mutation. As seen in Fig 2, there was no
protective effect of the loss of glucose in the urine with respect to change in glucose tolerance
(p = 0.67, Fig 2D, S3–S4 Figs) or HbA1c (p = 0.09 Fig 2B) over time in the mutation carriers.
There was also no difference in glucose tolerance at the last visit (p = 0.64, Fig 2C). Since treat-
ment with SGLT2 inhibitors is associated with decreased body weight, an increase in the
Table 2. The p.A343Vmutation in the family of the index case (No 45).
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haematocrit values [33] and an increase in total, LDL and HDL cholesterol concentration [34]
we also examined changes in BMI, hematocrit and cholesterol between carriers and non-carri-
ers. We did not observe any differences in the change in BMI (p = 0.33, Fig 2E and S5 Fig), cho-
lesterol (p = 0.14) or haematocrit (p = 0.10) between the two groups. There was furthermore
no difference in the change in triglycerides (p = 0.88) or HDL cholesterol (p = 0.20) between
the groups.
SLC5A1, but not SLC5A2 expression correlates with glucagon in human
pancreatic islets
The mRNA expression of the SGTL2 (SLC5A2) and SGLT1 (SLC5A1) genes was analysed in
RNA extracted from human islet donors (n = 131) using RNA sequencing. Expression of
SLC5A1 (mean log2CPM = 5.26) was much higher than the very low expression of SLC5A2
(mean log2CPM = -3.19. As a comparison glucagon has a mean expression of log2CPM = 15.02
and insulin log2CPM = 10.16). As disruption of SLC5A2 by siRNA has been shown to influence
glucagon (GCG) secretion [14] we further explored this by co-expression analyses. Expression of
SLC5A2 did show a strong correlation with the insulin gene (n = 131, r = 0.63, q-value<0.0001),
but not with the glucagon gene (Fig 4B, n = 131, r = -0.15, q-value = 0.19) or glucagon secretion
Fig 3. The p.A343Vmutated SGLT2 protein transports less glucose across the cell membrane.
Glucose uptake of the mutant HEK293 cells was lower as compared to wild type SGLT2 (p = 0.02). The open
bar describes the relative fluorescent signal as measured and calculated by the glucose uptake assay in the
HEK293 cell lines transfected with wild type SLC5A2 (n = 12). The closed bar describes the HEK293 cell
lines transfected with p.A343V mutated SLC5A2 (n = 12). The difference was tested between wild type-
transfected and mutant-transfected cell lines using student’s t-test. The error bars show the SEM, *p<0.05.
doi:10.1371/journal.pone.0146114.g003
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at 1 mM glucose (n = 54, r = -0.27, p = 0.11). SLC5A1 correlated with glucagon (Fig 4A, n = 131,
r = 0.53, q-value<0.0001), but not with insulin (n = 131, r = -0.15, q-value = 0.11) expression.
Discussion
The molecular genetic analyses demonstrated that the renal glycosuria in this family was due
to mutations in the SLC5A2 gene. While most of the individuals were heterozygous for a dele-
tion or a missense mutation in the SLC5A2 gene, the index case, a person with more severe
symptoms was compound heterozygous for both mutations. Given the long follow-up of this
family as part of the Botnia study [18] we could also examine whether chronic loss of glucose
in the urine had any influence on the changes in the glucose tolerance or the BMI. However,
we did not find any such effect, but we need to keep in mind that these data are restricted to a
single although large pedigree and we can therefore not generalize this observation to all carri-
ers of mutations in the SLC5A2 gene.
In the majority of other reported cases of familial renal glycosuria the causal mutation has
been located in the protein coding sequence of the SLC5A2 gene [35]. In our study a novel
frame shift deletion (c.300-303+2del) spanning the end of exon 3 and part of the splice site in
intron 3 of the SLC5A2 gene was found to be associated with glycosuria. All individuals carry-
ing this novel mutation in its heterozygous form tested repeatedly positive for glucose in the
urine (Fig 2A). In keeping with these findings heterozygous mutations in SLC5A2 have previ-
ously been shown to result in mild symptoms of FRG.
The deletion causes a frame shift that is predicted to introduce a stop codon at amino acid
residue 117, causing premature end of translation and resulting in a truncated peptide (S1 Fig)
with reduced function, as predicted by snpEff [23]. The resulting peptide would lack the trans-
membrane helices that are necessary for glucose transport [36].
The index case, a female member of the pedigree (No 45) had shown more severe symptoms
including postprandial hypoglycemia as well as chronic urinary and genital infections, pre-
dominantly mycotic candida infections. Because of the severe symptoms she was examined at
the Helsinki University Central Hospital in the 1970’s with a kidney biopsy that showed no
specific histological changes. However, she had excreted glucose already at low plasma glucose
concentrations.
We therefore hypothesized that she would have been homozygous for the deletion found in
the other family members. Unfortunately, we could not include her DNA in the exome
sequencing efforts as she had died from a gastric tumor in 1989, and no DNA had been taken
in the 70ies. We however imputed her genotype from her husband, daughter and grandchil-
dren and the most likely segregating variant in the SLC5A2 gene was a p.A343V mutation,
Fig 4. The gene expression of SLC5A2 and SLC5A1 in human pancreatic islets correlated with
glucagon gene expression. The mRNA expression of SLC5A1 (panel A, n = 131, r = 0.53, q-value<0.0001),
but not SLC5A2 (panel B, n = 131, r = -0.15, q-value = 0.19), correlates with the expression of the glucagon
gene or secretion of glucagon at 1 mM glucose (panel C, n = 54, r = -0.27, p = 0.11) in human islets.
doi:10.1371/journal.pone.0146114.g004
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which we confirmed by genotyping DNA from her gastric biopsy. The missense mutation (p.
A343V) is located in a helical structure in the hydrophilic chains on the extracellular side of the
membrane based on homology modeling of SGLT2 (SWISS-MODEL Repository [37,38]). This
helix together with another extracellular helical structure is supposed to be important for con-
formational changes necessary for sodium and glucose transport [36]. This was also tested by
expressing the mutation in HEK 293 cells, where it resulted in impaired glucose transport (Fig
3). It is therefore likely that the index case carried two damaging mutations in the SLC5A2 gene
resulting in an extremely low threshold for glucose reabsorption in the proximal tubule.
Recently a novel class of drugs has been introduced for the treatment of type 2 diabetes,
namely SGLT2 inhibitors [16,39–41] that mimic the effect of the mutations described above.
Taking advantage of the long follow-up of these family members, we also analyzed whether
chronic glycosuria would have beneficial effects on changes in the glucose tolerance over time.
Whereas the level of glycemia is strongly correlated with the degree of glycosuria in a popu-
lation with diabetes, this was not the case in the mutation carriers. Mutation carriers also did
not show less increase in AUCOGTT or HbA1c over time than non-carriers of the mutation (Fig
2D) as would be expected if chronic glycosuria would protect against deterioration of glycemia
and development of diabetes.
Although SGLT2 is predominantly found in the proximal tubule, it has been shown that the
alpha cells of human pancreatic islets also express SGLT2 as well as the high-affinity, low-
capacity transporter SGLT1 [14]. We confirmed the expression of these transporters at mRNA
level in 131 islet preparations from human cadaver donors. It has been suggested that SLC5A2
affects glucagon secretion in human islets [14], but we did not observe any correlation between
SLC5A2 and GCGmRNA or the glucagon secretion in the large islet sample (Fig 4B). Instead
the more highly expressed SGLT1 gene was strongly correlated with the expression of the glu-
cagon gene (Fig 4A). However, in contrast to previous data [14], this expression was not influ-
enced by the diabetic status of the donor. Interestingly, SLC5A2 was positively correlated with
the insulin gene, the consequence of which is unknown.
In conclusion, mutations in the SLC5A2 gene were the most likely cause of renal glycosuria
in this family. Compound heterozygosity of mutations in the SLC5A2 gene was associated with
a severe form of the disease characterized by chronic urogenital candida infections and post-
prandial hypoglycemia. In this family we found no evidence that chronic loss of glucose in the
urine would protect from deterioration of the glucose tolerance over time. This could be
another example of difficulties in targeting homeostatic mechanisms in human metabolism.
Supporting Information
S1 Fig. Alignment of the wild type and mutant SLC5A2 RNA translation to amino acids.
Wild type is the native sequence while deletion is from the RNA with the deleted 4 bases from
c.300-303+2del (2 deleted bases in the intronic region of the gene are not considered for sim-
plicity). The red portion of the deletion sequence aligns perfectly with the native protein
sequence, but the remaining sequence is frame shifted due to the deletion and shortly after the
mutation a stop codon is introduced (here represented by |).
(PDF)
S2 Fig. Genotyping using genotype specific primers showed that the index case (45) was a
carrier of the SLC5A2 p.A343V mutation. The figure shows the gel picture from a tapestation
analysis where lane B1 and C1 contains PCR product from the index case, lane D1 and E1 are
positive controls for the reference C-genotype, lane F1 and G1 are positive controls for the
alternative T-genotype and lane H1 and A2 are negative controls for the T-allele.
(PDF)
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S3 Fig. The glucose tolerance at the first and last visit. A) The median AUCOGTT value for all
the individuals at the first and the last visit. B) The absolute AUCOGTT for the non-carriers and
the carriers of the SLC5A2 c.300-303+2del mutation at the first and the last visit.
(TIF)
S4 Fig. Individual family member’s OGTT-curves at the first and the last visit.
(TIF)
S5 Fig. BMI at first and last visit. A) The median BMI for all the individuals at the first and
the last visit. B) The BMI for the non-carriers and the carriers of the SLC5A2 c.300-303+2del
mutation at the first and the last visit.
(TIF)
S6 Fig. The glucose uptake in SLC5A2 transfected cells is 10 times higher compared to
untransfected cells. Panel A shows the total amount of DNA in lysate from wells used for glu-
cose uptake assay (untransfected n = 2, transfected n = 6). Panel B show the relative glucose
uptake in untransfected and wild type SLC5A2 transfected HEK293 cells normalized to the
total DNA content of the wells (untransfected n = 2, transfected n = 3).  p<0.05,  p<0.001.
(TIF)
S1 Table. The cDNA sequence used for gene synthesis of wild type and mutant SLC5A2 to
be cloned into the pCMV6-Neo vector. The constructs were transfected into HEK293 cell
lines for glucose uptake studies.
(PDF)
S2 Table. The oligonucleotide sequences used for the genotyping of p.A343V in the index
case. The annealing temperature and the number of PCR cycles are indicated in the table.
(PDF)
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